PROFILE OF PATIENTS WITH MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS AT MERAUKE REGIONAL GENERAL HOSPITAL, MERAUKE REGENCY, SOUTH PAPUA, JANUARY 2021 – DECEMBER 2024

Luana N. Achmad (Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia)
Jimmi M. P. Aritonang (Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia)
Febtusia Puspitasari (Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia)
Ganda Pariama (Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia)

Journal of Innovation Research and Knowledge
Vol. 5 No. 8 (2026): Januari 2026

Pulmonary MDR-TB is tuberculosis that is resistant to first-line drugs, especially isoniazid and rifampicin, due to genetic mutations at drug target sites, so it requires combinations of drugs from Groups A and B, and if needed, Group C. This descriptive study used medical records of MDR-TB patients treated at Merauke Regional Hospital from January 2021 to December 2024 and was analyzed univariately with SPSS version 26. Most patients were 18–59 years old (90.6%), female (53.1%), and had a history of previous TB treatment (89.3%), with a small proportion experiencing treatment interruption and treatment failure. Comorbidities included diabetes mellitus (6.3%) and HIV (18.8%), and the mortality rate was relatively high at 40.6%.